title: High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.
abstract: The transformation of follicular lymphoma (FL) to high-grade histology occurs in up to 70% of patients. The role of hematopoietic stem cell transplantation (HSCT) in transformed FL is poorly defined. Twenty-four FL patients with histologically confirmed transformation to diffuse large B-cell lymphoma underwent unpurged autologous HSCT at our institution. Their median age was 56 yr. The median number of prior chemotherapies was 2 (range 1-6). Thirteen patients had residual nodal disease measuring more than 2 cm and four patients had bulky disease at the time of HSCT. Six patients had refractory disease at transplantation. At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively.
authors.affiliation: Department of Internal Medicine, Division of Hematology-Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. mehdi.hamadani@gmail.com
authors.forename: Mehdi
authors.initials: M
authors.lastname: Hamadani
authors.forename: Don M
authors.initials: DM
authors.lastname: Benson
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Lin
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Porcu
authors.forename: Kristie A
authors.initials: KA
authors.lastname: Blum
authors.forename: Steven M
authors.initials: SM
authors.lastname: Devine
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008224:Lymphoma, Follicular / Q000401:mortality / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000069283:Rituximab; D016879:Salvage Therapy / Q000401:mortality; D015996:Survival Rate; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab